In addition, patients with increased cardiometabolic risks are always characterized by elevated serum ADA levels, and these cardiometabolic risks include higher BMI (35), increased TC (36), hypertension (16), atherosclerosis (13), thrombosis (14), coronary artery calcification (37) and T2D (38). This evidence concerns the gene ADA and Venous thrombosis.